pharmaphorum’s Post

For US audiences only Exciting News in Medical Imaging! A recent GE HealthCare pharmacoeconomic study demonstrates that integrating a PET/CT scan with breast oncology tracer [18F]FES into the standard diagnostic workup for patients with metastatic or recurrent breast cancer has the potential to increase diagnostic accuracy - which ultimately has the potential to improve clinical and subsequent economic outcomes. Healthcare providers' ability to visualize estrogen receptor status with greater accuracy in the entire body reduces the need for repeated biopsies and allows clinicians to select more effective treatments. Using widely accepted statistical modelling methods, the study identified the potential to save the US healthcare system $142M over five years. I’m excited about the positive impact our research can have on patient care and healthcare resource use efficiency! 💡 #PrecisionCare #DiagnosticImaging #GEHealthCare #BreastCancer #Oncology This content is not intended for healthcare professionals or patients outside the U.S. https://lnkd.in/gcpSb4GC

GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and Economic Outcomes, Potentially Saving $142M Over Five... MARLBOROUGH, Mass.--(BUSINESS WIRE)--  GE HealthCare Pharmaco-Economic Study Demonstrates Adding Breast Oncology PET Tracer to Standard Workup of Patients with Metastatic or Recurrent Breast Cancer May Yield Beneficial Clinical and Economic Outcomes, Potentially Saving $142M Over Five Years in the US In a GE HealthCare sponsored pharmaco-economic study published in peer-reviewed journal PLOS ONE, the incidence, prevalence, diagnostic pathways, and treatments of different patients. via Business Wire Health: Medical Devices News

De-Escalated Neoadjuvant Weekly Nab-Paclitaxel With Trastuzumab and Pertuzumab vs Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab for HER2-Positive Early Breast Cancer The Lancet Oncology TAKE-HOME MESSAGE HELEN-006 was a phase III study that compared the efficacy of weekly nab-paclitaxel versus docetaxel and carboplatin, both in combination with trastuzumab and pertuzumab in Asian patients with HER2-positive stage II to III breast cancer. Nab-paclitaxel resulted in significantly higher pathological complete response rates (66.3% vs 57.6%; OR, 1.54). This was mostly driven by patients with hormone receptor–negative disease (OR, 2.62). The nab-paclitaxel regimen was associated with fewer grade ≥3 adverse events (30% vs 38%), except for neuropathy and transaminitis. The favourable toxicity profile and enhanced response rates support the integration of nab-paclitaxel combined with trastuzumab and pertuzumab into clinical practice for select populations of patients with HER2-positive early breast cancer, particularly those with hormone receptor–negative tumors.

We are excited to share our latest review, just published in Therapeutic Advances in Medical Oncology! Our work focuses on the growing role of ADCs, particularly Tisotumab Vedotin (TV), in the treatment of recurrent or metastatic cervical cancer (CC). Despite advances in immunotherapy, many patients continue to face limited treatment options when their disease progresses. This is where ADCs like TV are making a difference. Key highlights: 🧬 TV has shown significant promise in clinical trials, with ORR between 17.8% and 54.4% and PFS of 3.1–6.9 months in patients who have progressed beyond standard therapies. ⚡ Important challenges: • Identifying the most suitable timing for ADC administration in CC treatment. • Optimizing combination therapies to improve effectiveness while reducing resistance. • Managing specific toxicities such as ocular and neurological side effects. • Looking ahead, we believe ADCs will play a transformative role in targeted cancer therapies, providing new hope for improving both survival and quality of life for CC patients. 📚 Read the full article: https://lnkd.in/ewX8GxJP Many thanks to all the collaborators for their dedication and expertise! Floriana Camarda Mariachiara Paderno Camilla Nero Ilaria Sabatucci Lucia Musacchio vanda Salutari Humanitas San Pio X Humanitas Research Hospital #CervicalCancer #OncologyResearch #AntibodyDrugConjugates #TisotumabVedotin #CancerTherapy #MedicalResearch #CervicalCancerAwareness 

AI models predict the risk of future treatment discontinuation and nonadherence in women undergoing endocrine therapy for early stage breast cancer. Telemonitoring in oncology, informed by robust predictive analytics, could significantly improve treatment adherence and overall patient outcomes. A recent study of Estrogen receptor-positive breast cancer patients (constitutes approximately 70% of all breast cancer cases) found that 17% discontinued endocrine therapy (nonpersistance) and 41% developed nonadherence which may increase the risk of recurrance. We can do better. 229,695 female patients with early breast cancer were included in the study and followed for 5 years. The AI models developed were able to predict the future 6 month risk of nonpersistence and nonadherence. Identified factors such as younger age, past adherence behavior, number of treatments, and lower income level were associated with higher risk of nonpersistence and nonadherence. These results highlight the potential to anticipate nonadherence and nonpersistence and integrate proactive telemonitoring into clinical practice. This integration could increase support for patients and families, allow for real-time monitoring and early intervention, and help optimize resource allocation in health care settings. JAMA Network Open. 2024;7(5):e2411909. doi:10.1001/jamanetworkopen.2024.11909 #cancer #patientadvocacy

Pleased to share our latest research published in Immunotherapy investigating the prognostic value of the type of prior tyrosine kinase inhibitor (TKI) treatment—specifically sunitinib versus pazopanib—in pretreated metastatic renal cell carcinoma (mRCC) patients receiving nivolumab. Key Findings: - No significant difference in overall response rate, disease control rate, progression-free survival, or overall survival between patients pretreated with sunitinib versus pazopanib. - This suggests that neither TKI offers a clear advantage in priming the effectiveness of subsequent nivolumab therapy. Conclusion: Our results highlight the need for further research to better understand the impact of prior TKI choice on immunotherapy outcomes in mRCC patients. 🔗 For those interested in a deeper dive, you can access the full paper here: https://lnkd.in/eWXxJAkG A big thank you to all the co-authors and collaborators who contributed to this study! International Urology Cancer Summit OncoAlert OncoViews #RenalCellCarcinoma #Immunotherapy #OncologyResearch #CancerTreatment #TKI #Nivolumab #ResearchPublication

The Katherine phase III updated results are out - Aleix Prat MD, PhD https://lnkd.in/dycPNmaM Authors: Charles Geyer, Jr. Michael Untch Max Mano Prof. Dr. med. Sibylle Loibl Eleonora Restuccia #Cancer #CancerResearch #ClinicalTrial #BreastCancer #Medicine #Health #Oncology #OncoDaily

📅 Stomach Cancer Awareness Month | November 2024 📅 🔗 Explore Oncology CME/CE Conferences and Online Courses on eMedEvents - https://bit.ly/3YVoU8G 📊 Stat Alert: Stomach cancer represents about 1.5% of all new cancer cases in the U.S., yet its impact on patient health is profound, with thousands diagnosed each year. Given its unique challenges in early detection and treatment, it's crucial for healthcare professionals to stay informed on the latest advancements in oncology and gastric cancer research. By staying updated, HCPs can apply cutting-edge practices in diagnostics, targeted treatments, and patient management to improve outcomes. 🔗 Stay informed with the latest Oncology CME courses on eMedEvents #StomachCancerAwareness #Webcast #Pharmacology #OncologyCME #CancerCare #PharmacyTechnician #Oncology #Nephrology #PharmacyandMedicine #eMedEvents

MARIPOSA (NCT04487080), first-line ami+laz provided a statistically significant improvement in progression-free survival (PFS) vs osimertinib (osi) in patients (pts) with EGFR-mutant advanced NSCLC (HR, 0.70; P< 0.001), including in pts with a history of brain metastases (HR, 0.69; Cho Ann Oncol 2023;34:S1 #Lung Cancer—Non–Small Cell Metastatic

Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial) Duloxetine Effectiveness in Preventing Taxane-Related Neuropathy Key Findings Paclitaxel chemotherapy can lead to long-lasting neuropathy. However, a double-blind randomized trial revealed that duloxetine is a potentially effective medication for preventing both subjective and objective neuropathy in breast cancer patients undergoing paclitaxel treatment. Practical Solutions The study found that daily administration of duloxetine at specific doses during the first and second weeks of each chemotherapy cycle significantly reduced the occurrence and severity of neuropathic symptoms and objective neurophysiological measures. This suggests a practical and promising intervention to prevent taxane-related neuropathy in breast cancer patients undergoing paclitaxel chemotherapy. Value in Healthcare The results of this trial offer valuable insights for clinicians and patients, highlighting the potential of duloxetine to improve quality of life and treatment adherence by addressing a common side effect of paclitaxel chemotherapy, ultimately contributing to better patient outcomes and care management. https://lnkd.in/gMxFjezj #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics